<code id='0614A19CA2'></code><style id='0614A19CA2'></style>
    • <acronym id='0614A19CA2'></acronym>
      <center id='0614A19CA2'><center id='0614A19CA2'><tfoot id='0614A19CA2'></tfoot></center><abbr id='0614A19CA2'><dir id='0614A19CA2'><tfoot id='0614A19CA2'></tfoot><noframes id='0614A19CA2'>

    • <optgroup id='0614A19CA2'><strike id='0614A19CA2'><sup id='0614A19CA2'></sup></strike><code id='0614A19CA2'></code></optgroup>
        1. <b id='0614A19CA2'><label id='0614A19CA2'><select id='0614A19CA2'><dt id='0614A19CA2'><span id='0614A19CA2'></span></dt></select></label></b><u id='0614A19CA2'></u>
          <i id='0614A19CA2'><strike id='0614A19CA2'><tt id='0614A19CA2'><pre id='0614A19CA2'></pre></tt></strike></i>

          leisure time

          leisure time

          author:explore    Page View:4485
          Matts Take Column Illustration
          Molly Ferguson for STAT

          American medicine is a tragic paradox. An example: Cancer patients are likely dying as a result of drug shortages that occurred partly because generic chemotherapies have been allowed to become too cheap. At the same time, other patients are suffering, and perhaps dying, because the financial burden brought on by the expensive medicines they need is too high.

          Sit with that like a terrible Zen koan: Medicines are both too cheap and too expensive.

          advertisement

          How is that possible? A lot of it goes back to the 1984 Hatch-Waxman Act, which set up the ecosystem that determines the process by which drugs go from being expensive brands to cheap generics in the U.S.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          As JPM 2024 winds down, some health tech firms project optimism
          As JPM 2024 winds down, some health tech firms project optimism

          AdobeYou’rereadingthewebeditionofSTAT’sHealthTechnewsletter,ourguidetohowtechnologyistransformingthe

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

          IsnoonesafefromtheFTC?HasPfizerbottomedout?Andisbiotechfinallyback?Wecoverallthatandmorethisweekon“T